Susquehanna International Group
LXEO icon

Susquehanna International Group’s Lexeo Therapeutics LXEO Stock Holding History

Susquehanna International Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$175K Buy
30,500
+18,300
+150% +$130K ﹤0.01% 11834
2025
Q4 		$121K Buy
+12,200
New +$111K ﹤0.01% 11345

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's LXEO Position: Q1 2026 in Review

Susquehanna International Group increased its Lexeo Therapeutics (LXEO) stake by 27% in Q1 2026, buying an estimated $70.8K and bringing the position to 46,998 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #11112.

Susquehanna International Group first reported a position in LXEO in Q1 2024 and has held it in 7 quarters since. The position peaked at $367K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Susquehanna International Group held 46,998 shares of Lexeo Therapeutics worth $270K as of Q1 2026.
  • Susquehanna International Group bought 9,989 Lexeo Therapeutics shares in Q1 2026, an estimated $70.8K.
  • Lexeo Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11112 holding.
  • Susquehanna International Group first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Susquehanna International Group's Lexeo Therapeutics position peaked at $367K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.